

## Special Issue

# Multi-epitope Vaccines against Neglected, Emerging, and Re-emerging Global Diseases

### Message from the Guest Editor

Neglected Global Diseases are infectious diseases and other conditions that cause physical and cognitive impairments, including maternal, infant and child health conditions; neglected tropical diseases; as well as malaria, tuberculosis, and HIV/AIDS. As climate change pushes the natural selection of pathogens and their vectors and natural reservoirs, the risk of these neglected diseases emerging within a larger global population poses an even greater threat. Vaccination is still viewed as the most effective method of preventing these infectious diseases by inducing protective immunity. This Special Issue invites articles and reviews involving multi-epitope vaccine design against neglected, emerging, and re-emerging global diseases, as well as methodologies, novel evaluation, and prediction tools for vaccine design improvement. This issue also welcomes works involving the recombinant production and in vitro and/or in vivo validation of these chimeric vaccines.

### Guest Editor

Dr. Cerrone Cabanos

1. Graduate School of Agriculture, Kyoto University, Kyoto, Japan
2. Institute for Liberal Arts and Sciences, Kyoto University, Kyoto, Japan

### Deadline for manuscript submissions

closed (30 June 2024)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/152519](https://mdpi.com/si/152519)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).